

Nadia Harbeck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7058544/publications.pdf>

Version: 2024-02-01

233
papers

26,356
citations

17405

63
h-index

6979

154
g-index

244
all docs

244
docs citations

244
times ranked

22018
citing authors

#	ARTICLE	IF	CITATIONS
1	Awareness and Availability of Routine Germline <i></i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in Germany. <i>Breast Care</i> , 2022, 17, 40-46.	0.8	3
2	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecologic center in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 713-718.	0.8	9
3	Quality-of-life methodology in hormone receptor-“positive advanced breast cancer: Current tools and perspectives for the future. <i>Cancer Treatment Reviews</i> , 2022, 102, 102321.	3.4	4
4	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
5	Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. <i>Breast</i> , 2022, 62, S12-S16.	0.9	29
6	ABC6 Consensus: Assessment by a Group of German Experts. <i>Breast Care</i> , 2022, 17, 90-100.	0.8	6
7	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	5.8	21
8	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-“Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
9	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 556-567.	13.9	444
10	Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2-“ advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210812.	1.4	4
11	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. <i>Genome Biology</i> , 2022, 23, 52.	3.8	8
12	Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a-“case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 119.	0.4	1
13	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. <i>Npj Breast Cancer</i> , 2022, 8, 42.	2.3	9
14	De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-“): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 625-635.	5.1	30
15	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2-“ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	3.2	90
16	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. <i>Psycho-Oncology</i> , 2022, 31, 770-778.	1.0	4
17	Inter-“observer agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 191-205.	1.3	19
18	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2-“ Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	0.8	49

#	ARTICLE	IF	CITATIONS
19	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
20	Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy. <i>Breast Care</i> , 2022, 17, 501-507.	0.8	0
21	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 403-420.	0.8	43
22	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	3.2	65
23	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 421-429.	0.8	9
24	A look at current and potential treatment approaches for hormone receptor ⁺ positive, HER2 ⁻ negative early breast cancer. <i>Cancer</i> , 2022, 128, 2209-2223.	2.0	4
25	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
26	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	13.9	854
27	Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS609-TPS609.	0.8	3
28	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	1.9	6
29	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4995-5003.	3.2	6
30	ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. <i>Modern Pathology</i> , 2022, 35, 1804-1811.	2.9	4
31	Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 50-58.	0.8	2
32	Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. <i>Breast Care</i> , 2021, 16, 173-180.	0.8	3
33	Late Presentation at Primary Diagnosis of Breast Cancer: Patients TM Personality Characteristics and Attitudes. <i>Breast Care</i> , 2021, 16, 343-349.	0.8	0
34	First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. <i>Breast Care</i> , 2021, 16, 129-134.	0.8	3
35	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
36	St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. <i>Breast Care</i> , 2021, 16, 135-143.	0.8	90

#	ARTICLE	IF	CITATIONS
37	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Global Oncology, 2021, 7, 162-172.	0.8	38
38	Early response by <sc>MR</sc> imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the <sc>WSG ADAPT</sc> subtrials. International Journal of Cancer, 2021, 148, 2614-2627.	2.3	5
39	Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast Cancer Research, 2021, 23, 36.	2.2	7
40	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
41	Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2~ breast cancer resistant to endocrine therapy: VinoMetro~AGO-B-046. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3391-3400.	1.2	6
42	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics, 2021, 11, 733.	1.3	13
43	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 499-511.	5.1	260
44	Update Breast Cancer 2020 Part 5 ~ Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Und Frauenheilkunde, 2021, 81, 469-480.	0.8	6
45	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. European Journal of Cancer, 2021, 147, 40-50.	1.3	6
46	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18
47	Pathological complete response rate and survival in patients with <i>BRCA</i>-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).. Journal of Clinical Oncology, 2021, 39, 579-579.	0.8	3
48	Reply to K. Hashimoto and A. Shimomura. Journal of Clinical Oncology, 2021, 39, 1507-1508.	0.8	0
49	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.. Journal of Clinical Oncology, 2021, 39, 503-503.	0.8	18
50	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. Journal of Clinical Oncology, 2021, 39, 504-504.	0.8	3
51	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment~driven analyses from the ExteNET study. European Journal of Cancer, 2021, 150, 268-277.	1.3	3
52	Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2535-2544.	1.2	8
53	CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncology, 2021, 17, 2107-2122.	1.1	34
54	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist, 2021, 26, e1339-e1346.	1.9	16

#	ARTICLE	IF	CITATIONS
55	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
56	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	3.2	5
57	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6156-6163.	3.2	12
58	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	0.8	6
59	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	1.2	19
60	Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	1.5	15
61	Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 835.	1.1	4
62	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	1.7	11
63	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
64	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
65	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	1.3	24
66	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
67	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	0.8	20
68	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	0.8	51
69	Fifteen Years of <i>Breast Care</i> . <i>Breast Care</i> , 2021, 16, 97-98.	0.8	0
70	Risk-adapted adjuvant therapy of luminal early breast cancer in 2020. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 53-58.	0.9	4
71	Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet. <i>Breast Care</i> , 2021, 16, 475-483.	0.8	5
72	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73

#	ARTICLE	IF	CITATIONS
73	Noadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	2.3	9
74	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	1.3	14
75	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5
76	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	2.3	27
77	EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients. <i>Breast Care</i> , 2020, 15, 171-177.	0.8	9
78	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	3.2	120
79	Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?. <i>Breast Care</i> , 2020, 15, 527-533.	0.8	2
80	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	1.7	29
81	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	1.4	18
82	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
83	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094306.	1.4	44
84	Noadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1090-1100.	6.3	625
85	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
86	European Breast Cancer Conference 12, October 2-3, 2020: Interview with the Chairs. <i>Breast Care</i> , 2020, 15, 594-598.	0.8	0
87	Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020, 6, 21.	2.3	42
88	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	0.8	25
89	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
90	Cytoplasmic PPAR β is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. <i>Journal of Translational Medicine</i> , 2020, 18, 94.	1.8	19

#	ARTICLE	IF	CITATIONS
91	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	13.9	1,542
92	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124.	157.7	123
93	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β 1 Are Inversely Associated with Survival in Primary Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 330.	1.8	13
94	Breast cancer is a systemic disease optimally treated by a multidisciplinary team. <i>Nature Reviews Disease Primers</i> , 2020, 6, 30.	18.1	22
95	Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. <i>Clinical Breast Cancer</i> , 2020, 20, 439-447.	1.1	3
96	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2 α Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4242-4249.	3.2	29
97	Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial. , 2020, , .		2
98	Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks. <i>Radiation Oncology</i> , 2020, 15, 117.	1.2	18
99	De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 515-515.	0.8	12
100	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19033.	1.2	46
101	ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS601-TPS601.	0.8	10
102	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTTO clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 511-511.	0.8	0
103	Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 289-296.	1.0	7
104	Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 202-207.	0.3	65
105	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	1.3	11
106	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
107	Prognostic relevance of RIP140 and ER β expression in unifocal versus multifocal breast cancers: a preliminary report. <i>International Journal of Molecular Sciences</i> , 2019, 20, 418.	1.8	8
108	Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. <i>Cancers</i> , 2019, 11, 160.	1.7	68

#	ARTICLE	IF	CITATIONS
109	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	0.8	152
110	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	13.9	656
111	Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies. <i>Future Oncology</i> , 2019, 15, 1313-1322.	1.1	6
112	CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. <i>BioDrugs</i> , 2019, 33, 125-135.	2.2	75
113	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1016.	1.8	24
114	<p>Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 87-97.	1.0	13
115	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019, 14, 103-110.	0.8	131
116	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808.	0.8	85
117	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€“298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
118	<p>First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10427-10433.	0.9	9
119	Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. <i>Breast</i> , 2019, 48, S97-S102.	0.9	6
120	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	1.1	15
121	Truly personalized therapy â€” an end to the era of one size fits all. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 77-78.	12.5	8
122	Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and selfâ€“esteem in patients with early breast cancer. <i>Psycho-Oncology</i> , 2019, 28, 401-407.	1.0	24
123	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 500-500.	0.8	5
124	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. <i>International Journal of Oncology</i> , 2018, 52, 755-767.	1.4	15
125	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	12.5	129
126	ABC4 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2018, 13, 48-58.	0.8	7

#	ARTICLE	IF	CITATIONS
127	The safety of palbociclib for the treatment of advanced breast cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 325-330.	1.0	2
128	Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. <i>Oncologist</i> , 2018, 23, 403-409.	1.9	9
129	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. <i>Radiation Oncology</i> , 2018, 13, 25.	1.2	12
130	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
131	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018, 18, 175-183.	1.1	21
132	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. <i>Breast Care</i> , 2018, 13, 124-128.	0.8	4
133	Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. <i>Journal of Geriatric Oncology</i> , 2018, 9, 163-169.	0.5	10
134	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 115-126.	5.1	333
135	Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 249-256.	1.2	15
136	Advances in targeting HER2-positive breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 55-59.	0.9	34
137	Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. <i>BMC Medical Genomics</i> , 2018, 11, 80.	0.7	13
138	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	13.9	805
139	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. <i>Breast Care</i> , 2018, 13, 285-291.	0.8	16
140	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 904-915.	5.1	648
141	Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1318-1323.	0.5	7
142	Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018, 101, 123-133.	1.3	59
143	Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878235.	1.4	5
144	Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival. <i>Translational Oncology</i> , 2018, 11, 1090-1096.	1.7	13

#	ARTICLE	IF	CITATIONS
145	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial. <i>Clinical Breast Cancer</i> , 2018, 18, e1103-e1110.	1.1	0
146	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. <i>BMC Cancer</i> , 2018, 18, 431.	1.1	15
147	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
148	Phase III study of tasisib (GDC-0032) + fulvestrant (FULV) vs FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA1006-LBA1006.	0.8	116
149	Mammakarzinom bei der alten und geriatrischen Patientin. , 2018, , 401-416.		0
150	Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 324-331.	1.0	23
151	Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1701-1712.	1.2	40
152	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1637-1647.	1.2	29
153	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. <i>Breast Care</i> , 2017, 12, 101-106.	0.8	109
154	Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1107-1122.	1.2	18
155	Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines. <i>Drugs in R and D</i> , 2017, 17, 569-583.	1.1	5
156	LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. <i>Molecular Oncology</i> , 2017, 11, 1508-1526.	2.1	19
157	Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. <i>Breast</i> , 2017, 34, S99-S103.	0.9	42
158	The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 661-668.	1.1	9
159	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 573-583.	1.1	149
160	Breast cancer. <i>Lancet, The</i> , 2017, 389, 1134-1150.	6.3	1,568
161	Survival of de novo stage IV breast cancer patients over three decades. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 509-519.	1.2	30
162	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 63-72.	1.1	35

#	ARTICLE	IF	CITATIONS
163	Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study. <i>Radiotherapy and Oncology</i> , 2017, 122, 2-10.	0.3	13
164	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
165	eHealth solutions for therapy management in oncology. <i>Breast Cancer Management</i> , 2017, 6, 101-106.	0.2	12
166	Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1318.	1.8	8
167	RE: Post-traumatic Stress as the Primary Cause for Cognitive Declineâ€”Not the Whole Story, and Perhaps No Story at All. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	1
168	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)â€”Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptorâ€”Positive Phase II Randomized Trialâ€”Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017, 35, 3046-3054.	0.8	114
169	Mammakarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-16.		0
170	Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. <i>Future Oncology</i> , 2016, 12, 1359-1367.	1.1	33
171	Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer. <i>Breast Care</i> , 2016, 11, 411-417.	0.8	5
172	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	5.1	1,344
173	Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. <i>Breast</i> , 2016, 28, 5-12.	0.9	51
174	A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. <i>Oncologist</i> , 2016, 21, 789-794.	1.9	38
175	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
176	HER2-positive breast cancer: neoadjuvant and adjuvant therapy. , 2016, , 29-49.		0
177	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw049.	3.0	1
178	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016, 34, 2341-2349.	0.8	246
179	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	0.8	315
180	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2â€” advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	72

#	ARTICLE	IF	CITATIONS
181	eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy. <i>JMIR Cancer</i> , 2016, 2, e14.	0.9	13
182	EHealth Acceptance and New Media Preferences for Therapy Assistance Among Breast Cancer Patients. <i>JMIR Cancer</i> , 2016, 2, e13.	0.9	33
183	Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. <i>Anticancer Research</i> , 2016, 36, 3185-90.	0.5	0
184	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 575.	0.7	28
185	Breast Cancer Is Our Global Responsibility. <i>Breast Care</i> , 2015, 10, 360-360.	0.8	6
186	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	13.9	1,239
187	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 351-357.	1.1	35
188	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576.	3.2	71
189	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
190	OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. <i>Oncology Letters</i> , 2015, 9, 418-424.	0.8	13
191	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015, 10, 124-130.	0.8	82
192	Tailoring therapiesâ€“improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
193	Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv099-djv099.	3.0	73
194	Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. <i>Breast</i> , 2015, 24, S44-S48.	0.9	22
195	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 315ra188.	5.8	261
196	Adjuvant radiotherapy after breast conserving surgery â€“ A comparative effectiveness research study. <i>Radiotherapy and Oncology</i> , 2015, 114, 28-34.	0.3	29
197	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 456-468.	3.2	153
198	Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: An Integrated Safety Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2750-2757.	0.8	98

#	ARTICLE	IF	CITATIONS
199	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2014, 10, 21-40.	1.1	12
200	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
201	Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow. <i>Cancer Treatment Reviews</i> , 2014, 40, 434-444.	3.4	88
202	uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. <i>Breast Cancer Research</i> , 2014, 16, 428.	2.2	201
203	Afatinib in the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1039-1047.	1.9	33
204	Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1437-1444.	0.8	72
205	Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. <i>Breast Care</i> , 2014, 9, 52-59.	0.8	6
206	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 524-524.	0.8	1
207	Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations. <i>Drugs</i> , 2013, 73, 1665-1680.	4.9	6
208	WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. <i>Trials</i> , 2013, 14, 261.	0.7	87
209	Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 839-850.	1.1	20
210	St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion. <i>Breast Care</i> , 2013, 8, 102-109.	0.8	123
211	German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3531-3539.	0.8	82
212	A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 508-508.	0.8	6
213	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS652-TPS652.	0.8	7
214	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS649-TPS649.	0.8	0
215	Lost in Translation? Estrogen Receptor Status and Endocrine Responsiveness in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 686-689.	0.8	28
216	ABC1 Consensus Conference - a German Perspective. <i>Breast Care</i> , 2012, 7, 52-59.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Treatment of breast cancer during pregnancy: an observational study. <i>Lancet Oncology</i> , The, 2012, 13, 887-896.	5.1	224
218	A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1149-1159.	1.1	72
219	Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 237-246.	1.1	83
220	Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 2273-2281.	1.3	164
221	Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 Å— FEC versus 3 Å— FEC/3 Å— Docetaxel. <i>BMC Cancer</i> , 2011, 11, 140.	1.1	40
222	Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2â€œOverexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. <i>Journal of Clinical Oncology</i> , 2011, 29, 3351-3357.	0.8	456
223	St. Gallen 2011: Summary of the Consensus Discussion. <i>Breast Care</i> , 2011, 6, 136-141.	0.8	194
224	Angiogenesis inhibitors in the management of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010, 22, 79-86.	0.9	15
225	Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2874-2880.	0.8	184
226	Personalized treatment of early-stage breast cancer: Present concepts and future directions. <i>Cancer Treatment Reviews</i> , 2010, 36, 584-594.	3.4	51
227	Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1028-1029.	3.0	33
228	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 303-309.	1.1	134
229	Multicenter Validation of a Gene Expressionâ€œBased Prognostic Signature in Lymph Nodeâ€œNegative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1665-1671.	0.8	328
230	Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2002, 94, 116-128.	3.0	548
231	Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). <i>Cancer Research</i> , 2002, 62, 4617-22.	0.4	143
232	Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1. <i>Journal of the National Cancer Institute</i> , 2001, 93, 913-920.	3.0	414
233	Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. <i>Breast Care</i> , 0, , 1-10.	0.8	1